360 related articles for article (PubMed ID: 26419478)
1. TNF-α: a treatment target or cause of sarcoidosis?
Amber KT; Bloom R; Mrowietz U; Hertl M
J Eur Acad Dermatol Venereol; 2015 Nov; 29(11):2104-11. PubMed ID: 26419478
[TBL] [Abstract][Full Text] [Related]
2. Anti-TNF therapeutics for the treatment of sarcoidosis.
Crommelin HA; Vorselaars AD; van Moorsel CH; Korenromp IH; Deneer VH; Grutters JC
Immunotherapy; 2014; 6(10):1127-43. PubMed ID: 25428650
[TBL] [Abstract][Full Text] [Related]
3. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA
Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Tolerance of Anti-Tumor Necrosis Factor α Agents in Cutaneous Sarcoidosis: A French Study of 46 Cases.
Heidelberger V; Ingen-Housz-Oro S; Marquet A; Mahevas M; Bessis D; Bouillet L; Caux F; Chapelon-Abric C; Debarbieux S; Delaporte E; Duval-Modeste AB; Fain O; Joly P; Marchand-Adam S; Monfort JB; Noël N; Passeron T; Ruivard M; Sarrot-Reynauld F; Verrot D; Bouvry D; Fardet L; Chosidow O; Sève P; Valeyre D
JAMA Dermatol; 2017 Jul; 153(7):681-685. PubMed ID: 28564695
[TBL] [Abstract][Full Text] [Related]
5. Biologic Therapy in the Treatment of Cutaneous Sarcoidosis: A Literature Review.
Dai C; Shih S; Ansari A; Kwak Y; Sami N
Am J Clin Dermatol; 2019 Jun; 20(3):409-422. PubMed ID: 30895525
[TBL] [Abstract][Full Text] [Related]
6. Etanercept ameliorates sarcoidosis arthritis and skin disease.
Khanna D; Liebling MR; Louie JS
J Rheumatol; 2003 Aug; 30(8):1864-7. PubMed ID: 12913948
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them.
Baughman RP; Lower EE; Drent M
Sarcoidosis Vasc Diffuse Lung Dis; 2008 Dec; 25(2):76-89. PubMed ID: 19382527
[TBL] [Abstract][Full Text] [Related]
8. Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists.
Thielen AM; Barde C; Saurat JH; Laffitte E
Dermatology; 2009; 219(1):59-62. PubMed ID: 19468200
[TBL] [Abstract][Full Text] [Related]
9. Tumour necrosis factor in sarcoidosis and its potential for targeted therapy.
Baughman RP; Iannuzzi M
BioDrugs; 2003; 17(6):425-31. PubMed ID: 14614765
[TBL] [Abstract][Full Text] [Related]
10. Steroid-resistant sarcoidosis: is antagonism of TNF-alpha the answer?
Denys BG; Bogaerts Y; Coenegrachts KL; De Vriese AS
Clin Sci (Lond); 2007 Mar; 112(5):281-9. PubMed ID: 17261090
[TBL] [Abstract][Full Text] [Related]
11. Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future concepts.
Sweiss NJ; Curran J; Baughman RP
Clin Dermatol; 2007; 25(3):341-6. PubMed ID: 17560312
[TBL] [Abstract][Full Text] [Related]
12. Infliximab therapy balances regulatory T cells, tumour necrosis factor receptor 2 (TNFR2) expression and soluble TNFR2 in sarcoidosis.
Verwoerd A; Hijdra D; Vorselaars AD; Crommelin HA; van Moorsel CH; Grutters JC; Claessen AM
Clin Exp Immunol; 2016 Aug; 185(2):263-70. PubMed ID: 27158798
[TBL] [Abstract][Full Text] [Related]
13. Practical eminence and experience-based recommendations for use of TNF-α inhibitors in sarcoidosis.
Drent M; Cremers JP; Jansen TL; Baughman RP
Sarcoidosis Vasc Diffuse Lung Dis; 2014 Jul; 31(2):91-107. PubMed ID: 25078637
[TBL] [Abstract][Full Text] [Related]
14. Treatment of sarcoidosis -- from a basic science point of view.
Moller DR
J Intern Med; 2003 Jan; 253(1):31-40. PubMed ID: 12588536
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases.
Dhaille F; Viseux V; Caudron A; Dadban A; Tribout C; Boumier P; Clabaut A; Lok C
Dermatology; 2010; 220(3):234-7. PubMed ID: 20185892
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor-alpha antagonist-induced sarcoidosis.
Clementine RR; Lyman J; Zakem J; Mallepalli J; Lindsey S; Quinet R
J Clin Rheumatol; 2010 Sep; 16(6):274-9. PubMed ID: 20808167
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement.
Oliver SJ; Kikuchi T; Krueger JG; Kaplan G
Clin Immunol; 2002 Mar; 102(3):225-36. PubMed ID: 11890709
[TBL] [Abstract][Full Text] [Related]
18. Sarcoidosis as a systemic disease.
Sehgal VN; Riyaz N; Chatterjee K; Venkatash P; Sharma S
Clin Dermatol; 2014; 32(3):351-63. PubMed ID: 24767183
[TBL] [Abstract][Full Text] [Related]
19. Targeting the TNF-alpha pathway in sarcoidosis.
Antoniu SA
Expert Opin Ther Targets; 2010 Jan; 14(1):21-9. PubMed ID: 20001207
[TBL] [Abstract][Full Text] [Related]
20. Refractory sarcoidosis responding to infliximab.
Roberts SD; Wilkes DS; Burgett RA; Knox KS
Chest; 2003 Nov; 124(5):2028-31. PubMed ID: 14605086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
